RT Journal Article
SR Electronic
T1 Real-time monitoring of COVID-19 dynamics using automated trend fitting and anomaly detection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.02.20186502
DO 10.1101/2020.09.02.20186502
A1 Thibaut Jombart
A1 Stéphane Ghozzi
A1 Dirk Schumacher
A1 Quentin J Leclerc
A1 Mark Jit
A1 Stefan Flasche
A1 Felix Greaves
A1 Tom Ward
A1 Rosalind M Eggo
A1 Emily Nightingale
A1 Sophie Meakin
A1 Oliver J Brady
A1 Centre for Mathematical Modelling of Infectious Diseases COVID-19 Working Group
A1 Graham F Medley
A1 Michael Höhle
A1 W John Edmunds
YR 2020
UL http://medrxiv.org/content/early/2020/09/03/2020.09.02.20186502.abstract
AB As several countries gradually release social distancing measures, rapid detection of new localised COVID-19 hotspots and subsequent intervention will be key to avoiding large-scale resurgence of transmission. We introduce ASMODEE (Automatic Selection of Models and Outlier Detection for Epidemics), a new tool for detecting sudden changes in COVID-19 incidence. Our approach relies on automatically selecting the best (fitting or predicting) model from a range of user-defined time series models, excluding the most recent data points, to characterise the main trend in an incidence. We then derive prediction intervals and classify data points outside this interval as outliers, which provides an objective criterion for identifying departures from previous trends. We also provide a method for selecting the optimal breakpoints, used to define how many recent data points are to be excluded from the trend fitting procedure. The analysis of simulated COVID-19 outbreaks suggest ASMODEE compares favourably with a state-of-art outbreak-detection algorithm while being simpler and more flexible. We illustrate our method using publicly available data of NHS Pathways reporting potential COVID-19 cases in England at a fine spatial scale, for which we provide a template automated analysis pipeline. ASMODEE is implemented in the free R package trendbreaker.Competing Interest StatementThe authors have declared no competing interest.Funding Statement The named authors (OB, JE, RE, TJ, MJ, SM, EN) had the following sources of funding: OB was funded by a Sir Henry Wellcome Fellowship funded by the Wellcome Trust (206471/Z/17/Z). RE receives funding from HDR UK (grant number: MR/S003975/1). SF is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (Grant number 208812/Z/17/Z). TJ receives funding from the Global Challenges Research Fund (GCRF) project RECAP managed through RCUK and ESRC (ES/P010873/1), the UK Public Health Rapid Support Team funded by the United Kingdom Department of Health and Social Care and from the National Institute for Health Research (NIHR) - Health Protection Research Unit for Modelling Methodology. MJ receives funding from the Bill and Melinda Gates foundation (grant number: INV-003174) and the NIHR (grant numbers: 16/137/109 and HPRU-2012-10096). EN receives funding from the Bill and Melinda Gates Foundation (grant number: OPP1183986). MJ and JE receive funding from European Commission project EpiPose (101003688). SM receives funding from the Wellcome Trust (grant: 210758/Z/18/Z). SFlasche receives funding from the Wellcome Trust (grant: 208812/Z/17/Z). The following funding sources are acknowledged as providing funding for the working group authors. Alan Turing Institute (AE). BBSRC LIDP (BB/M009513/1: DS). This research was partly funded by the Bill & Melinda Gates Foundation (INV-001754: MQ; INV-003174: KP, MJ, YL; NTD Modelling Consortium OPP1184344: CABP, GFM; OPP1180644: SRP; OPP1183986: ESN; OPP1191821: KOR, MA). BMGF (OPP1157270: KA). DFID/Wellcome Trust (Epidemic Preparedness Coronavirus research programme 221303/Z/20/Z:KvZ). DTRA (HDTRA1-18-1-0051: JWR). Elrha R2HC/UK DFID/Wellcome Trust/This research was partly funded by the National Institute for Health Research (NIHR) using UK aid from the UK Government to support global health research. The views expressed in this publication are those of the author(s) and not necessarily those of the NIHR or the UK Department of Health and Social Care (KvZ). ERC Starting Grant (#757699: JCE, MQ, RMGJH). This project has received funding from the European Union s Horizon 2020 research and innovation programme - project EpiPose (101003688: KP, MJ, PK, RCB, YL). This research was partly funded by the Global Challenges Research Fund (GCRF) project RECAP managed through RCUK and ESRC (ES/P010873/1: AG, CIJ, TJ). HDR UK (MR/S003975/1: RME). NIHR (16/136/46: BJQ; 16/137/109: BJQ, CD, FYS, MJ, YL; Health Protection Research Unit for Immunisation NIHR200929: NGD, FGS; Health Protection Research Unit for Modelling Methodology HPRU-2012-10096: TJ, FGS; NIHR200929: MJ; PR-OD-1017-20002: AR). Royal Society (Dorothy Hodgkin Fellowship: RL; RP\EA\180004: PK). UK DHSC/UK Aid/NIHR (ITCRZ 03010: HPG). UK MRC (LID DTP MR/N013638/1: GRGL, QJL, NRW; MC_PC_19065: AG, NGD, RME, SC, TJ, YL; MR/P014658/1: GMK). Authors of this research receive funding from UK Public Health Rapid Support Team funded by the United Kingdom Department of Health and Social Care (TJ). Wellcome Trust (206250/Z/17/Z: AJK, TWR; 206471/Z/17/Z: OJB; 208812/Z/17/Z: SC, SFlasche; 210758/Z/18/Z: SFunk, JM, SA, JH, NIB). No funding (AKD, AMF, CJVA, DCT, SH, YWDC). The UK Public Health Rapid Support Team is funded by UK aid from the Department of Health and Social Care and is jointly run by Public Health England and the London School of Hygiene & Tropical Medicine. The University of Oxford and Kings College London are academic partners. The views expressed in this publication are those of the authors and not necessarily those of the National Health Service, the National Institute for Health Research or the Department of Health and Social Care. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/A: this work only uses publicly available dataAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll scripts and data are publicly available on github (see links in the manuscript). https://github.com/reconhub/trendbreaker https://gitlab.com/stephaneghozzi/asmodee-trendbreaker-evaluation https://github.com/thibautjombart/nhs_pathways_monitoring https://covid19-nhs-pathways-asmodee.netlify.app/